SCHEMBL5952664

SCHEMBL5952664

CCCNC(=O)c1c[nH]nc1COC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.37
DPP4 P27487 2/20 0.37
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.35
KMT2A Q03164 3/20 0.35
HTT P42858 2/20 0.35
MEN1 O00255 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TSHR P16473 1/20 0.35
CCNE2 O96020 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5952351 0.81 DPP4 (0.43) POLBL3MBTL1THRBRECQLTDP1
SCHEMBL5952936 0.81 ALDH1A1 (0.36) ALDH1A1KMT2AHTTMEN1KDM4E
SCHEMBL5952390 0.80 CNR2 (0.39) POLBL3MBTL1ALDH1A1KMT2AKDM4E
SCHEMBL15705197 0.78 ALDH1A1 (0.30) ALDH1A1MAPTHPGDHTTHSD17B10
SCHEMBL5952397 0.78 USP2 (0.33) TDP1ALDH1A1MAPTHPGDHTT
SCHEMBL13374019 0.77 POLB (0.40) POLBL3MBTL1THRBRECQLTDP1
SCHEMBL5952180 0.76 KMT2A (0.42) L3MBTL1ALDH1A1MAPTKMT2AMEN1
SCHEMBL161102 0.75 POLB (0.43) POLBL3MBTL1THRBRECQLTDP1
SCHEMBL5951769 0.71 POLB (0.40) POLBL3MBTL1THRBRECQLTDP1
SCHEMBL13374013 0.70 MAPK1 (0.46) POLBALDH1A1GAAHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 POLB 2261/4885L3MBTL1 4599/4885THRB 2693/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A POLB 2841/4885L3MBTL1 4187/4885THRB 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.